Multinational phase 3 study of ripretinib versus sunitinib for advanced GIST after imatinib failure

The multitarget TKI sunitinib is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. The multinational phase 3 INTRIGUE trial compared the switch-control TKI ripretinib versus sunitinib for advanced GIST after treatment with imatinib. Ripretinib was not superior to sunitinib in terms of PFS. However, ripretinib had meaningful clinical activity, fewer grade 3 or 4 adverse events, and better scores on patient-reported outcome measures of tolerability.